The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
An article from
Dive Brief
//
Gene editing
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout
New drug could be game changer for people with high cholesterol
Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62% - Eli L
Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial
One dose of gene-editing drug cut bad cholesterol 62% for months in small trial
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
Pharmalittle: We're reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Gene-editing drugs are opening a new frontier in medicine
So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a…
Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a…
Drugmaker Eli Lilly is testing a new experimental drug that could be a game changer for treating high cholesterol.
Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.
The interim Phase I trial data was only from 35 people, but results look good so far.
The interim Phase I trial data was only from 35 people, but results look good so far.
